Folgen
Vikas Prasad
Vikas Prasad
Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University in St Louis
Bestätigte E-Mail-Adresse bei wustl.edu
Titel
Zitiert von
Zitiert von
Jahr
German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
K Rahbar, H Ahmadzadehfar, C Kratochwil, U Haberkorn, M Schäfers, ...
Journal of Nuclear Medicine 58 (1), 85-90, 2017
8452017
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules
RP Baum, V Prasad, D Müller, C Schuchardt, A Orlova, A Wennborg, ...
Journal of nuclear medicine 51 (6), 892-897, 2010
3522010
Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT
V Prasad, V Ambrosini, M Hommann, D Hoersch, S Fanti, RP Baum
European journal of nuclear medicine and molecular imaging 37, 67-77, 2010
2982010
Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours
D Kaemmerer, L Peter, A Lupp, S Schulz, J Sänger, V Prasad, H Kulkarni, ...
European journal of nuclear medicine and molecular imaging 38, 1659-1668, 2011
1732011
Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors
D Kaemmerer, L Peter, A Lupp, S Schulz, J Sänger, RP Baum, V Prasad, ...
International journal of clinical and experimental pathology 5 (3), 187, 2012
1632012
Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions
V Prasad, RP Baum
QJ Nucl Med Mol Imaging 54 (1), 61-67, 2010
1552010
Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET/CT in primary prostate cancer
N Woythal, R Arsenic, C Kempkensteffen, K Miller, JC Janssen, K Huang, ...
Journal of Nuclear Medicine 59 (2), 238-243, 2018
1512018
PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study
M Fellner, RP Baum, V Kubíček, P Hermann, I Lukeš, V Prasad, F Rösch
European Journal of Nuclear Medicine and Molecular Imaging 37, 834-834, 2010
1342010
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms
RP Baum, HR Kulkarni, A Singh, D Kaemmerer, D Mueller, V Prasad, ...
Oncotarget 9 (24), 16932, 2018
1332018
Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours
LM Dilz, T Denecke, IG Steffen, V Prasad, LF Von Weikersthal, UF Pape, ...
European Journal of Cancer 51 (10), 1253-1262, 2015
1332015
2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors
T Simon, B Hero, JH Schulte, H Deubzer, P Hundsdoerfer, ...
Klinische Pädiatrie 229 (03), 147-167, 2017
1202017
The status of neuroendocrine tumor imaging: from darkness to light?
L Bodei, A Sundin, M Kidd, V Prasad, IM Modlin
Neuroendocrinology 101 (1), 1-17, 2015
1172015
Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions
V Prasad, IG Steffen, G Diederichs, MR Makowski, P Wust, W Brenner
Molecular imaging and biology 18, 428-436, 2016
1142016
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
K Oberg, E Krenning, A Sundin, L Bodei, M Kidd, M Tesselaar, ...
Endocrine connections 5 (5), 174-187, 2016
1122016
NET blood transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive
M Pavel, H Jann, V Prasad, I Drozdov, IM Modlin, M Kidd
Neuroendocrinology 104 (2), 170-182, 2016
1032016
177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer
WP Fendler, C Kratochwil, H Ahmadzadehfar, K Rahbar, RP Baum, ...
Nuklearmedizin. Nuclear Medicine 55 (3), 123-128, 2016
1022016
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
D Kaemmerer, V Prasad, W Daffner, D Hörsch, G Klöppel, M Hommann, ...
World journal of gastroenterology: WJG 15 (46), 5867, 2009
972009
Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours
NF Schreiter, W Brenner, M Nogami, R Buchert, A Huppertz, UF Pape, ...
European journal of nuclear medicine and molecular imaging 39, 72-82, 2012
952012
Receptor PET/CT imaging of neuroendocrine tumors
RP Baum, V Prasad, M Hommann, D Hörsch
PET in Oncology, 225-242, 2008
952008
Child–Pugh Classification: Time to Abandon?
B Kok, JG Abraldes
Seminars in liver disease 39 (01), 096-103, 2019
852019
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20